Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: United States Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

NCT04074928
View directory record Official record
Conditions
Influenza, Human, Virus Diseases
Interventions
QIVc, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 47 Months
Enrollment
2,414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
47
States / cities
Mobile, Alabama • Anaheim, California • Downey, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

NCT00414011
View directory record Official record
Conditions
Epithelium, Corneal
Interventions
Moxifloxacin, Gatifloxacin
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 26, 2026, 7:24 AM EDT
Recruiting No phase listed Observational

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

NCT06193928
View directory record Official record
Conditions
Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Interventions
Livmarli
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 26, 2026, 7:24 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Recombinant Influenza Vaccination in U.S. Nursing Homes

NCT03965195
View directory record Official record
Conditions
Influenza, Influenza -Like Illness, Influenza, Human
Interventions
Recombinant Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
18 Years to 120 Years
Enrollment
1,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 26, 2026, 7:24 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Getting to Zero Among HHI MSM in the American South

NCT05075967
View directory record Official record
Conditions
HIV Infections
Interventions
Health Access Coalitions, Social Media, Peer Support, Promoting Human Autonomy Support & Empathy (PHASE)
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
15 Years and older · Male only
Enrollment
2,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 26, 2026, 7:24 AM EDT
Completed No phase listed Observational

Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Chart Review of Pediatric SMA Patients Outside of the United States

NCT06178393
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 5 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 26, 2026, 7:24 AM EDT
Withdrawn No phase listed Observational

Study of the Sudden Heart Failure Participant Population in the US

NCT03566264
View directory record Official record
Conditions
Heart Decompensation
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 26, 2026, 7:24 AM EDT
Completed No phase listed Observational Results available

Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)

NCT04820673
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sarecycline
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
9 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1

NCT02898779
View directory record Official record
Conditions
Malaria
Interventions
Primaquine, R-Primaquine, S-Primaquine, SR Primaquine
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Oxford, Mississippi
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Phase 3 Interventional

A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

NCT00208156
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
San Diego, California • Atlanta, Georgia • Las Vegas, Nevada + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 26, 2026, 7:24 AM EDT
Recruiting Phase 2 Interventional

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT05832229
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 7:24 AM EDT
Completed No phase listed Observational

A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System

NCT04807439
View directory record Official record
Conditions
Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases
Interventions
SYNERGY XLV (Megatron) Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
New Haven, Connecticut • Clearwater, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Not applicable Interventional Results available

Overnight Closed Loop Study in U.S.

NCT01857973
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Hybrid Closed Loop
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Escondido, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

NCT01769456
View directory record Official record
Conditions
HIV Infection
Interventions
PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 17 Years · Male only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Initial Evaluation of Photorefractive Keratectomy in U.S. Army Personnel

NCT00413673
View directory record Official record
Conditions
Myopia
Interventions
PRK
Procedure
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

NCT01423825
View directory record Official record
Conditions
HIV Infections
Interventions
Sub C gp140 Vaccine, MF59C.1 Adjuvant, Sodium chloride
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Evaluation of Contrast Sensitivity and Disability Glare in Refractive Surgery, a Sub-Study of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

NCT00413868
View directory record Official record
Conditions
Myopia
Interventions
LASIK, PRK, Small target contrast sensitivity and disability glare
Procedure · Behavioral
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Phase 3 Interventional

Crux Biomedical Vena Cava Filter Study - United States

NCT01120509
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Inferior Vena Cava Filter
Device
Lead sponsor
Crux Biomedical
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Orange, California • Sacramento, California • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Not applicable Interventional Results available

Brief Educational Video for Patients Prescribed LTBI Treatment

NCT05412212
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
LTBI video intervention
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Not applicable Interventional Results available

Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy

NCT00955201
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 26, 2026, 7:24 AM EDT
Completed No phase listed Observational Results available

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

NCT07072793
View directory record Official record
Conditions
COVID-19 (Coronavirus Disease 2019)
Interventions
nirmatrelvir-ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
131,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 26, 2026, 7:24 AM EDT
Completed No phase listed Observational

Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States

NCT06393387
View directory record Official record
Conditions
Hiv, HIV-1-infection, HIV Infections
Interventions
DTG/3TC versus BIC/F/TAF
Drug
Lead sponsor
Midway Specialty Care Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Not applicable Interventional

Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014

NCT01764269
View directory record Official record
Conditions
Fever
Interventions
text message surveillance for fever
Other
Lead sponsor
Columbia University
Other
Eligibility
24 Months to 59 Months
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 26, 2026, 7:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

NCT05374525
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir OLI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 26, 2026, 7:24 AM EDT